HRP20120707T1 - Spojevi za liječenje hepatitisa c - Google Patents
Spojevi za liječenje hepatitisa c Download PDFInfo
- Publication number
- HRP20120707T1 HRP20120707T1 HRP20120707AT HRP20120707T HRP20120707T1 HR P20120707 T1 HRP20120707 T1 HR P20120707T1 HR P20120707A T HRP20120707A T HR P20120707AT HR P20120707 T HRP20120707 T HR P20120707T HR P20120707 T1 HRP20120707 T1 HR P20120707T1
- Authority
- HR
- Croatia
- Prior art keywords
- hcv
- inhibitors
- alkyl
- methyl
- carbonyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 16
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- -1 hydroxy, benzyloxy Chemical group 0.000 claims abstract 22
- 125000000217 alkyl group Chemical group 0.000 claims abstract 21
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 11
- 239000001257 hydrogen Substances 0.000 claims abstract 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract 6
- 150000002367 halogens Chemical class 0.000 claims abstract 6
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 5
- 125000001424 substituent group Chemical group 0.000 claims abstract 5
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000002541 furyl group Chemical group 0.000 claims abstract 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims abstract 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims abstract 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims abstract 3
- 125000001544 thienyl group Chemical group 0.000 claims abstract 3
- 125000001425 triazolyl group Chemical group 0.000 claims abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract 2
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims abstract 2
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims abstract 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims abstract 2
- 125000002971 oxazolyl group Chemical group 0.000 claims abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims abstract 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims abstract 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims abstract 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims 15
- OTDWHDOTZWWCFA-UHFFFAOYSA-N 12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2,4,6,8,10,13,15,17-nonaene-9-carboxamide Chemical compound C=1N2C3=CC=CC=C3C=C2C2=CC=CC=C2C2=C(C(=O)N)C2=1 OTDWHDOTZWWCFA-UHFFFAOYSA-N 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 108010036941 Cyclosporins Proteins 0.000 claims 2
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 229940047124 interferons Drugs 0.000 claims 2
- 229940047122 interleukins Drugs 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 claims 1
- 229940122750 HCV entry inhibitor Drugs 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 125000005981 pentynyl group Chemical group 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98952407P | 2007-11-21 | 2007-11-21 | |
| PCT/US2008/083978 WO2009067481A1 (en) | 2007-11-21 | 2008-11-19 | Compounds for the treatment of hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120707T1 true HRP20120707T1 (hr) | 2012-09-30 |
Family
ID=40263273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120707AT HRP20120707T1 (hr) | 2007-11-21 | 2012-09-05 | Spojevi za liječenje hepatitisa c |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8129367B2 (pl) |
| EP (2) | EP2209784B1 (pl) |
| JP (1) | JP5306366B2 (pl) |
| CN (1) | CN101918406B (pl) |
| DK (1) | DK2209784T3 (pl) |
| ES (1) | ES2390732T3 (pl) |
| HR (1) | HRP20120707T1 (pl) |
| PL (1) | PL2209784T3 (pl) |
| PT (1) | PT2209784E (pl) |
| SI (1) | SI2209784T1 (pl) |
| WO (1) | WO2009067481A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| WO2009120733A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
| US8138171B2 (en) * | 2008-03-27 | 2012-03-20 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors |
| AU2009228337A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
| EP2814830A1 (en) * | 2012-02-17 | 2014-12-24 | F.Hoffmann-La Roche Ag | Tricyclic compounds and methods of use therefor |
| JP6306002B2 (ja) * | 2012-07-18 | 2018-04-04 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ | （４ｂＳ，５ａＲ）−１２−シクロヘキシル−Ｎ−（Ｎ，Ｎ−ジメチルスルファモイル）−３−メトキシ−５ａ−（（１Ｒ，５Ｓ）−３−メチル−３，８−ジアザビシクロ［３．２．１］オクタン−８−カルボニル）−４ｂ，５，５ａ，６−テトラヒドロベンゾ［３，４］シクロプロパ［５，６］アゼピノ［１，２−Ａ］インドール−９−カルボキサミドを製造するための新規な方法および中間体 |
| EP2792360A1 (en) * | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| CN115856144B (zh) * | 2022-12-19 | 2023-07-07 | 华夏生生药业(北京)有限公司 | 一种氟康唑原料药及注射液中三甲基碘化亚砜杂质的检测方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| DK1719773T3 (da) | 2004-02-24 | 2009-06-29 | Japan Tobacco Inc | Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| BRPI0516972A (pt) | 2004-10-26 | 2008-09-30 | Angeletti P Ist Ricerche Bio | composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7521443B2 (en) | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521442B2 (en) | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| ES2343914T3 (es) * | 2006-05-25 | 2010-08-12 | Bristol-Myers Squibb Company | Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo. |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| CN103224506A (zh) * | 2006-12-20 | 2013-07-31 | P.安杰莱蒂分子生物学研究所 | 抗病毒的吲哚 |
| US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7998951B2 (en) | 2007-03-05 | 2011-08-16 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| CN101679437B (zh) * | 2007-03-13 | 2013-04-17 | 百时美施贵宝公司 | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
| US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7521444B2 (en) | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7541353B2 (en) | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7538103B2 (en) | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US20090018163A1 (en) | 2007-07-11 | 2009-01-15 | Bristol-Myers Squibb Company | Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| CN101918410B (zh) * | 2007-11-20 | 2013-02-27 | 百时美施贵宝公司 | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
| US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
-
2008
- 2008-11-18 US US12/272,974 patent/US8129367B2/en active Active
- 2008-11-19 PT PT08852063T patent/PT2209784E/pt unknown
- 2008-11-19 CN CN2008801251283A patent/CN101918406B/zh not_active Expired - Fee Related
- 2008-11-19 PL PL08852063T patent/PL2209784T3/pl unknown
- 2008-11-19 SI SI200830801T patent/SI2209784T1/sl unknown
- 2008-11-19 EP EP08852063A patent/EP2209784B1/en not_active Not-in-force
- 2008-11-19 DK DK08852063.0T patent/DK2209784T3/da active
- 2008-11-19 ES ES08852063T patent/ES2390732T3/es active Active
- 2008-11-19 EP EP12176732.1A patent/EP2518073B1/en not_active Not-in-force
- 2008-11-19 WO PCT/US2008/083978 patent/WO2009067481A1/en active Application Filing
- 2008-11-19 JP JP2010535034A patent/JP5306366B2/ja not_active Expired - Fee Related
-
2012
- 2012-01-19 US US13/353,864 patent/US20120115847A1/en not_active Abandoned
- 2012-09-05 HR HRP20120707AT patent/HRP20120707T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2209784T1 (sl) | 2013-02-28 |
| PT2209784E (pt) | 2012-10-09 |
| JP5306366B2 (ja) | 2013-10-02 |
| WO2009067481A1 (en) | 2009-05-28 |
| EP2209784A1 (en) | 2010-07-28 |
| US8129367B2 (en) | 2012-03-06 |
| CN101918406B (zh) | 2013-04-17 |
| JP2011504179A (ja) | 2011-02-03 |
| EP2209784B1 (en) | 2012-08-01 |
| PL2209784T3 (pl) | 2012-12-31 |
| EP2518073A1 (en) | 2012-10-31 |
| DK2209784T3 (da) | 2012-10-29 |
| CN101918406A (zh) | 2010-12-15 |
| US20120115847A1 (en) | 2012-05-10 |
| US20090130057A1 (en) | 2009-05-21 |
| EP2518073B1 (en) | 2015-08-26 |
| ES2390732T3 (es) | 2012-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120707T1 (hr) | Spojevi za liječenje hepatitisa c | |
| ES2230084T3 (es) | Peptidos macrociclicos que inhiben la proteasa ns3 del virus de la hepatitis c. | |
| HRP20120440T1 (hr) | Inhibitori virusa hepatitisa c | |
| KR20090111353A (ko) | Ｈｃｖ ｎｓ3 프로테아제 억제제로서 매크로시클릭 화합물 | |
| ES2470568T3 (es) | Inhibidores macroc�clicos del virus de la hepatitis C | |
| HRP20110194T1 (hr) | Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b | |
| CA2761650C (en) | Macrocyclic compounds as hepatitis c virus inhibitors | |
| HRP20120706T1 (hr) | Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c | |
| US20050065073A1 (en) | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | |
| JP2010521483A5 (pl) | ||
| HRP20160410T1 (hr) | Inhibitori hepatitis c virusa | |
| NZ573275A (en) | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | |
| CA2708150A1 (en) | Fluorinated tripeptide hcv serine protease inhibitors | |
| EP1904516A2 (en) | Hepatitis c virus inhibitors | |
| HRP20130063T1 (hr) | Inhibitori virusa hepatitisa c | |
| JP2010521476A5 (pl) | ||
| JP5977819B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| WO2007120595A2 (en) | Amines for the treatment of hcv | |
| JP2010532352A5 (pl) | ||
| EP2219453A1 (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors | |
| WO2009134987A1 (en) | Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors | |
| WO2009070689A1 (en) | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease | |
| SG174474A1 (en) | Organic compounds and their uses | |
| US20090053175A1 (en) | Substitute pyrrolidine derivatives | |
| CA2712940A1 (en) | Heteroaryl-containing tripeptide hcv serine protease inhibitors |